

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 21, 2025

Daudi

RRID:CVCL_0008

Type: Cell Line

Proper Citation

(RRID:CVCL_0008)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0008

Proper Citation: (RRID:CVCL_0008)

Sex: Male

Defining Citation: [PMID:170370](#), [PMID:216485](#), [PMID:1325212](#), [PMID:2052620](#), [PMID:2140233](#), [PMID:2470097](#), [PMID:2985879](#), [PMID:2998993](#), [PMID:3026973](#), [PMID:3034807](#), [PMID:3080238](#), [PMID:3100061](#), [PMID:3116544](#), [PMID:3159941](#), [PMID:3518877](#), [PMID:3785169](#), [PMID:3874327](#), [PMID:3905596](#), [PMID:4122458](#), [PMID:4174339](#), [PMID:4178827](#), [PMID:4321974](#), [PMID:4364259](#), [PMID:4878906](#), [PMID:5021706](#), [PMID:6186604](#), [PMID:6200433](#), [PMID:6231253](#), [PMID:6286763](#), [PMID:6500159](#), [PMID:6547209](#), [PMID:6582512](#), [PMID:6592381](#), [PMID:6806672](#), [PMID:6935474](#), [PMID:6954533](#), [PMID:7316467](#), [PMID:7849311](#), [PMID:8176200](#), [PMID:8197130](#), [PMID:8301159](#), [PMID:8515068](#), [PMID:8558913](#), [PMID:8558920](#), [PMID:8568269](#), [PMID:8847894](#), [PMID:9192833](#), [PMID:9473234](#), [PMID:9510473](#), [PMID:9685479](#), [PMID:9737686](#), [PMID:9738977](#), [PMID:9973220](#), [PMID:10739008](#), [PMID:11021758](#), [PMID:11226526](#), [PMID:11894933](#), [PMID:12145705](#), [PMID:12967475](#), [PMID:14504097](#), [PMID:15028022](#), [PMID:19358282](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20454443](#), [PMID:22460905](#), [PMID:22885699](#), [PMID:24590883](#), [PMID:25355872](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29892436](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:35839778](#)

Comments: Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620., Omics: Virome analysis using RNAseq., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: Deep antibody staining analysis., Population: African; Kenyan., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human variation

panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

Category: Cancer cell line

Name: Daudi

Synonyms: DAUDI, NK-10A, NK-10a, NK 10a, NK10a, N, GM03190, GM3190, GM03190A, GM17346

Cross References: BTO:BTO_0001561, CLO:CLO_0002708, CLO:CLO_0013411, CLO:CLO_0013740, CLO:CLO_0050991, EFO:EFO_0002169, MCCL:MCC:0000141, CLDB:cl993, CLDB:cl994, CLDB:cl995, CLDB:cl996, CLDB:cl997, CLDB:cl998, CLDB:cl999, CLDB:cl5181, AddexBio:C0003010/4669, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ATCC:CCL-213, ATCC:CRL-7917, BCRC:60192, BioGRID_ORCS_Cell_line:1081, BioSample:SAMN00808283, BioSample:SAMN01821546, BioSample:SAMN01821623, BioSample:SAMN03472413, BioSample:SAMN10987948, cancercellines:CVCL_0008, CCRID:1101HUM-PUMC000134, CCRID:1102HUM-NIFDC00053, CCRID:3101HUMTCHu140, CCRID:4201HUM-CCTCC00097, CCTCC:GDC0097, Cell_Model_Passport:SIDM00845, CGH-DB:9195-4, ChEMBL-Cells:ChEMBL3307579, ChEMBL-Targets:ChEMBL614281, CLS:302009, Coriell:GM03190, Coriell:GM17346, Cosmic:687838, Cosmic:906831, Cosmic:919135, Cosmic:929815, Cosmic:931102, Cosmic:932762, Cosmic:991548, Cosmic:996304, Cosmic:998716, Cosmic:1019315, Cosmic:1037701, Cosmic:1070708, Cosmic:1071878, Cosmic:1086326, Cosmic:1093789, Cosmic:1118470, Cosmic:1176616, Cosmic:1191690, Cosmic:1517663, Cosmic:1995384, Cosmic:2649240, Cosmic:2759407, Cosmic:2760061, Cosmic:2814537, Cosmic:2815216, Cosmic:2823073, Cosmic-CLP:906831, dbMHC:48767, DepMap:ACH-000786, DSMZ:ACC-78, DSMZCellDive:ACC-78, ECACC:85011437, ECACC:94071449, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:906831, GEO:GSM99381, GEO:GSM862859, GEO:GSM862860, GEO:GSM862861, GEO:GSM862862, GEO:GSM886973, GEO:GSM888042, GEO:GSM960117, GEO:GSM960118, GEO:GSM960119, GEO:GSM960120, GEO:GSM1374459, GEO:GSM1669726, GEO:GSM3150242, IARC_TP53:143, IARC_TP53:21144, ICLC:HTL95024, IGRhCellID:Daudi, IHW:IHW09366, IPD-IMGT/HLA:10471, IZSLER:BS TCL 104, JCRB:JCRB9071, KCB:KCB 2012116YJ, KCLB:10213, LiGeA:CCLE_233, LINCS_LDP:LCL-2018, Lonza:490, NCBI_Iran:C112, PharmacDB:Daudi_283_2019, PRIDE:PXD004181, PRIDE:PXD012087, PRIDE:PXD030304, Progenetix:CVCL_0008, PubChem_Cell_line:CVCL_0008, RCB:RCB1640, TKG:TKG 0362, Wikidata:Q54828579

ID: CVCL_0008

Record Creation Time: 20220427T215744+0000

Record Last Update: 20250420T105715+0000

Ratings and Alerts

No rating or validation information has been found for Daudi.

Warning: Discontinued: ATCC; CRL-7917

Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620., Omics: Virome analysis using RNAseq., Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: Deep antibody staining analysis., Population: African; Kenyan., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: Human variation panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

McNutt SW, et al. (2024) Phosphorylation-Driven Epichaperome Assembly: A Critical Regulator of Cellular Adaptability and Proliferation. Research square.

Takami M, et al. (2024) Anti-V α 24J β 18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an Fc γ RII (CD32)-dependent Manner. Cancer research communications, 4(2), 446.

Zhao GX, et al. (2024) Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection. Cell reports. Medicine, 5(5), 101573.

Huang J, et al. (2024) Assembly and activation of EBV latent membrane protein 1. Cell, 187(18), 4996.

Liu P, et al. (2024) Chidamide represses MYC expression and might improve survival for patients with double expressor lymphoma. American journal of cancer research, 14(6), 2921.

Pfeffer K, et al. (2024) A method for screening functional anti-Treg antibodies using a Treg-like cell line. *Journal of leukocyte biology*.

Dong J, et al. (2023) ?? T cell-mediated cytotoxicity against patient-derived healthy and cancer cervical organoids. *Frontiers in immunology*, 14, 1281646.

Wu L, et al. (2023) CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. *Cell reports. Medicine*, 4(2), 100917.

Ogasawara A, et al. (2023) Preclinical development of ZED8, an ⁸⁹Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy. *European journal of nuclear medicine and molecular imaging*, 50(2), 287.

Okano F, et al. (2023) Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950. *Cancer research communications*, 3(4), 640.

Aranda-Orgilles B, et al. (2023) Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies. *Cancer immunology research*, 11(7), 946.

Shimasaki N, et al. (2023) Size control of induced pluripotent stem cells colonies in two-dimensional culture for differentiation into functional monocyte-like cells. *Cytotherapy*, 25(12), 1338.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Groß E, et al. (2023) SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. *Cancers*, 15(11).

Janezic EM, et al. (2023) A novel, label-free, pre-equilibrium assay to determine the association and dissociation rate constants of therapeutic antibodies on living cells. *British journal of pharmacology*.

Hu YZ, et al. (2023) Multiple functions and regulatory network of miR-150 in B lymphocyte-related diseases. *Frontiers in oncology*, 13, 1140813.

Buonato JM, et al. (2022) Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain. *Molecular cancer therapeutics*, 21(7), 1171.

Xiong X, et al. (2022) Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors. *Cell*, 185(7), 1157.

Liu Y, et al. (2022) CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. *International journal of cancer*, 150(7), 1141.